Cargando…

Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis

To evaluate the changes in the gut microbiota associated with changes in the biochemical markers of nonalcoholic fatty liver disease (NAFLD) after a lifestyle intervention with the Mediterranean diet. Participants (n = 297) from two centers of PREDIMED-Plus trial (Prevención con Dieta Mediterránea)...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez-Pérez, Ana María, Ruiz-Limón, Patricia, Salas-Salvadó, Jordi, Vioque, Jesús, Corella, Dolores, Fitó, Montse, Vidal, Josep, Atzeni, Alessandro, Torres-Collado, Laura, Álvarez-Sala, Andrea, Martínez, María Ángeles, Goday, Albert, Benaiges, David, García-Gavilán, Jesús, Bernal López, María Rosa, Moreno-Indias, Isabel, Tinahones, Francisco J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288930/
https://www.ncbi.nlm.nih.gov/pubmed/37345236
http://dx.doi.org/10.1080/19490976.2023.2223339
_version_ 1785062175834898432
author Gómez-Pérez, Ana María
Ruiz-Limón, Patricia
Salas-Salvadó, Jordi
Vioque, Jesús
Corella, Dolores
Fitó, Montse
Vidal, Josep
Atzeni, Alessandro
Torres-Collado, Laura
Álvarez-Sala, Andrea
Martínez, María Ángeles
Goday, Albert
Benaiges, David
García-Gavilán, Jesús
Bernal López, María Rosa
Moreno-Indias, Isabel
Tinahones, Francisco J.
author_facet Gómez-Pérez, Ana María
Ruiz-Limón, Patricia
Salas-Salvadó, Jordi
Vioque, Jesús
Corella, Dolores
Fitó, Montse
Vidal, Josep
Atzeni, Alessandro
Torres-Collado, Laura
Álvarez-Sala, Andrea
Martínez, María Ángeles
Goday, Albert
Benaiges, David
García-Gavilán, Jesús
Bernal López, María Rosa
Moreno-Indias, Isabel
Tinahones, Francisco J.
author_sort Gómez-Pérez, Ana María
collection PubMed
description To evaluate the changes in the gut microbiota associated with changes in the biochemical markers of nonalcoholic fatty liver disease (NAFLD) after a lifestyle intervention with the Mediterranean diet. Participants (n = 297) from two centers of PREDIMED-Plus trial (Prevención con Dieta Mediterránea) were divided into three different groups based on the change tertile in the Hepatic Steatosis Index (HSI) or the Fibrosis−4 score (FIB−4) between baseline and one year of intervention. One-year changes in HSI were: tertile 1 (T1) (−24.9 to −7.51), T2 (−7.5 to −1.86), T3 (−1.85 to 13.64). The most significant differences in gut microbiota within the year of intervention were observed in the T1 and T3. According to the FIB−4, participants were categorized in non-suspected fibrosis (NSF) and with indeterminate or suspected fibrosis (SF). NSF participants showed higher abundances of Alcaligenaceae, Bacteroidaceae, Bifidobacteriaceae, Clostridiaceae, Enterobacteriaceae, Peptostreptococcaceae, Verrucomicrobiaceae compared to those with SF. Then, participants were divided depending on the FIB−4 tertile of change: T1 (−89.60 to −5.57), T2 (−5.56 to 11.4), and T3 (11.41 to 206.24). FIB−4 T1 showed a decrease in Akkermansia and an increase in Desulfovibrio. T2 had an increase in Victivallaceae, Clostridiaceae, and Desulfovibrio. T3 showed a decrease in Enterobacteriaceae, and an increase in Sutterella, Faecalibacterium, and Blautia. A relation between biochemical index changes of NAFLD/NASH (HSI and FIB−4) and gut microbiota changes were found. These observations highlight the importance of lifestyle intervention in the modulation of gut microbiota and the management of metabolic syndrome and its hepatic manifestations.
format Online
Article
Text
id pubmed-10288930
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-102889302023-06-24 Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis Gómez-Pérez, Ana María Ruiz-Limón, Patricia Salas-Salvadó, Jordi Vioque, Jesús Corella, Dolores Fitó, Montse Vidal, Josep Atzeni, Alessandro Torres-Collado, Laura Álvarez-Sala, Andrea Martínez, María Ángeles Goday, Albert Benaiges, David García-Gavilán, Jesús Bernal López, María Rosa Moreno-Indias, Isabel Tinahones, Francisco J. Gut Microbes Research Paper To evaluate the changes in the gut microbiota associated with changes in the biochemical markers of nonalcoholic fatty liver disease (NAFLD) after a lifestyle intervention with the Mediterranean diet. Participants (n = 297) from two centers of PREDIMED-Plus trial (Prevención con Dieta Mediterránea) were divided into three different groups based on the change tertile in the Hepatic Steatosis Index (HSI) or the Fibrosis−4 score (FIB−4) between baseline and one year of intervention. One-year changes in HSI were: tertile 1 (T1) (−24.9 to −7.51), T2 (−7.5 to −1.86), T3 (−1.85 to 13.64). The most significant differences in gut microbiota within the year of intervention were observed in the T1 and T3. According to the FIB−4, participants were categorized in non-suspected fibrosis (NSF) and with indeterminate or suspected fibrosis (SF). NSF participants showed higher abundances of Alcaligenaceae, Bacteroidaceae, Bifidobacteriaceae, Clostridiaceae, Enterobacteriaceae, Peptostreptococcaceae, Verrucomicrobiaceae compared to those with SF. Then, participants were divided depending on the FIB−4 tertile of change: T1 (−89.60 to −5.57), T2 (−5.56 to 11.4), and T3 (11.41 to 206.24). FIB−4 T1 showed a decrease in Akkermansia and an increase in Desulfovibrio. T2 had an increase in Victivallaceae, Clostridiaceae, and Desulfovibrio. T3 showed a decrease in Enterobacteriaceae, and an increase in Sutterella, Faecalibacterium, and Blautia. A relation between biochemical index changes of NAFLD/NASH (HSI and FIB−4) and gut microbiota changes were found. These observations highlight the importance of lifestyle intervention in the modulation of gut microbiota and the management of metabolic syndrome and its hepatic manifestations. Taylor & Francis 2023-06-21 /pmc/articles/PMC10288930/ /pubmed/37345236 http://dx.doi.org/10.1080/19490976.2023.2223339 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Research Paper
Gómez-Pérez, Ana María
Ruiz-Limón, Patricia
Salas-Salvadó, Jordi
Vioque, Jesús
Corella, Dolores
Fitó, Montse
Vidal, Josep
Atzeni, Alessandro
Torres-Collado, Laura
Álvarez-Sala, Andrea
Martínez, María Ángeles
Goday, Albert
Benaiges, David
García-Gavilán, Jesús
Bernal López, María Rosa
Moreno-Indias, Isabel
Tinahones, Francisco J.
Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis
title Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis
title_full Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis
title_fullStr Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis
title_full_unstemmed Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis
title_short Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis
title_sort gut microbiota in nonalcoholic fatty liver disease: a predimed-plus trial sub analysis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288930/
https://www.ncbi.nlm.nih.gov/pubmed/37345236
http://dx.doi.org/10.1080/19490976.2023.2223339
work_keys_str_mv AT gomezperezanamaria gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis
AT ruizlimonpatricia gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis
AT salassalvadojordi gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis
AT vioquejesus gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis
AT corelladolores gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis
AT fitomontse gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis
AT vidaljosep gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis
AT atzenialessandro gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis
AT torrescolladolaura gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis
AT alvarezsalaandrea gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis
AT martinezmariaangeles gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis
AT godayalbert gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis
AT benaigesdavid gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis
AT garciagavilanjesus gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis
AT bernallopezmariarosa gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis
AT morenoindiasisabel gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis
AT tinahonesfranciscoj gutmicrobiotainnonalcoholicfattyliverdiseaseapredimedplustrialsubanalysis